886 results on '"El‐Rayes, Bassel F."'
Search Results
52. Supplementary Data from PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
53. Supplementary Data from Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer
54. Supplementary Figure from Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
55. Supplementary Figures 1 - 6 from CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer
56. Supplementary Figure Legends from CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer
57. Data from CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer
58. Supplementary Tables 1 - 4 from CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer
59. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases
60. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458)
61. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
62. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
63. Induction Therapy in Localized Pancreatic Cancer
64. Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer
65. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
66. The association of the CARE Frailty Index with survival among older adults with pancreatic cancer.
67. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma
68. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview
69. Hypoxia inducible factor-1α: Its role in colorectal carcinogenesis and metastasis
70. High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma
71. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer
72. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease
73. Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study
74. Chapter 1 - Computational approaches for anticancer drug design
75. Molecularly Targeted Therapies in Pancreatic Cancer
76. Inhibiting heat shock protein 90 and the ubiquitin‐proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells
77. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis
78. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer
79. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
80. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
81. Comparing VIP and PD‐L1 expression as cancer biomarkers
82. Abstract 104: Targeting NAD(P)H:quinone oxidoreductase 1 (NQO1) in pancreatic ductal adenocarcinoma: An in silco, in vitro and in vivo approach
83. Abstract 1059: Paricalcitol, hydroxychloroquine and gemcitabine promote antitumor effects and modulate immune profile in pancreatic ductal adenocarcinoma
84. Abstract 1439: Meta-analysis of the NQO1 gene C609T polymorphism: Increased risk of colorectal cancer
85. Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
86. Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
87. The prognostic significance of TP53 mutations in patients with right-sided and left-sided colorectal cancer.
88. The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations.
89. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
90. Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma
91. Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
92. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer
93. Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization
94. Targeting T regulatory cells: Their role in colorectal carcinoma progression and current clinical trials
95. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
96. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
97. Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?
98. Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.
99. Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.
100. Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.